SPHK1{sphingosine kinase 1}rabbit.pAb
- Known as:
- SPHK1{sphingosine phosphorylation catalyst 1}host: rabbit.pAb
- Catalog number:
- 201-20-5539
- Product Quantity:
- 0.2ml
- Category:
- -
- Supplier:
- Shanghai Sunred
- Gene target:
- SPHK1{sphingosine kinase 1}rabbit.pAb
Related genes to: SPHK1{sphingosine kinase 1}rabbit.pAb
- Gene:
- ANKK1 NIH gene
- Name:
- ankyrin repeat and kinase domain containing 1
- Previous symbol:
- -
- Synonyms:
- X-kinase
- Chromosome:
- 11q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-13
- Date modifiied:
- 2013-01-10
Related products to: SPHK1{sphingosine kinase 1}rabbit.pAb
guanine nucleotide binding protein alpha inhibiting activity polypeptide 1 (GNAI1) polyclonal antibody kinase suppressor of ras (KSR) polyclonal antibody(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-1-pivaloyl-erythro-sphingosine C29H57N3O3Si CAS: 114275-42-2(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-1-pivaloyl-erythro-sphingosine CAS: 114275-42-2 Formula: C29H57N3O3Si(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine C24H49N3O2Si CAS: 114299-64-8(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine CAS: 114299-64-8 Formula: C24H49N3O2Si(Ala286)-Calmodulin-Dependent Protein Kinase II (281-302) 98% C111H191N39O29S2 CAS:(Ala286)_Calmodulin_Dependent Protein Kinase II (281_302) Salt _ Binding _ Synonym (Ala286)_CaMK_II (281_302) SumFormula C111H191N39O29S2(Ala286)_Calmodulin_Dependent Protein Kinase II (281_302) Salt _ Binding _ Synonym (Ala286)_CaMK_II (281_302) SumFormula C111H191N39O29S2(Alpha)_ 1 _ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_1_ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2 Related articles to: SPHK1{sphingosine kinase 1}rabbit.pAb
- Obesity, characterized by abnormal fat accumulation with comorbidities, continues to increase dramatically, particularly in the pediatric population. Identifying the environmental and genetic causes underlying the development of obesity during early childhood is crucial for establishing preventive and protective treatments for this complex disease. We aimed to investigate genetic variants related to non-syndromic early-onset childhood obesity. - Source: PubMed
Publication date: 2026/04/29
Olgun Celebioglu Hazal BanuOzturk Ayse PinarPoyrazoglu SukranTuncer Feyza Nur - Obesity represents a significant health challenge worldwide, with an increasing trend and high prevalence in Mexico. This metabolic disease, characterized by an increase in body mass index (BMI), leads to abnormal fat accumulation that contributes to several pathologies, and is determined by a complex interaction between diet, lifestyle and genetic factors, such as single nucleotide variants (SNVs) that may influence appetite regulation, adipose tissue function, energy metabolism, reward mechanisms, motivation, food intake behavior control, energy expenditure, fatty acid transport, lipid accumulation, lipolysis, insulin sensitivity, glucose metabolism, among other biochemical processes. However, the frequency of obesity-associated genetic variants remains poorly characterized in Mexican populations-which are highly admixed-as demonstrated by population genetic studies which have established the influence of this admixture in the prevalence and distribution of obesity-related SNVs. - Source: PubMed
Publication date: 2026/04/10
Perezcano CarlosSánchez AndreaCendejas GerardoBorrayo FranciscoPérez-Coria MarianaPérez-Hernández Gerardo - Obesity has been increasing at an uncontrolled rate. Genetic variations have been shown to contribute to a higher risk of developing the condition, due to impaired satiety regulation, predisposition to addictive eating behaviors, or even specific personality traits. This study aimed to evaluate the influence of gene polymorphisms related to the dopaminergic system on developing severe obesity. - Source: PubMed
Publication date: 2026/04/16
Teixeira Myrela RibeiroFelício Rafaela de Freitas MartinsAssis Izadora Sthephanie da SilvaGouvea Laura WendlingAbreu Gabriella MedeirosSouza Ritiele Bastos dePalhinha LohannaJunior Mario Camposde Mello Neto Cícero BrasileiroMaya-Monteiro Clarissa MenezesBozza Patrícia TorresCarneiro João Regis IvarZembrzuski Verônica MarquesSalum Kaio Cezar Rodriguesda Fonseca Ana Carolina ProençaKohlrausch Fabiana Barzotto - The present study aimed to: (i) compare a patient group with solely alcohol use disorder (AUD) to a group with poly-substance use disorder (poly-SUD) regarding sociodemographic background, morbidity, mortality, and the prevalence of the A1 allele of the Taq1A polymorphism. (ii) Investigate whether gender, age, poly-SUD, and the prevalence of the A1 allele or interactions among these factors, are associated with mortality risk over an 18-year follow-up period. - Source: PubMed
Rauwolf Kerstin KBerggren UlfBalldin JanHasselgren Bune CarolineBerglund Kristina J - The role of neurotransmitter systems in the pathology and management of psychiatric disorders is well documented. Targeting these systems has remained the mainstay of standard pharmacological interventions, with typical and atypical antipsychotics demonstrating effectiveness in reducing both positive and negative symptoms of schizophrenia. However, their clinical efficacy and side effect profiles vary among individuals due to genetic differences. This review aims to examine key genetic variants in the dopaminergic neurotransmitter system that influence antipsychotic response, with particular emphasis on clinically relevant single-nucleotide polymorphisms (SNPs), to support improved treatment outcome prediction and precision psychiatry. Polymorphisms in genes encoding dopamine receptors, transporters, and metabolising enzymes have been associated with variability in antipsychotic efficacy and susceptibility to adverse effects. Across multiple studies, the catechol-O-methyltransferase (COMT) Val158Met (rs4680) polymorphism and the dopamine D2 receptor/ANKK1 Taq1A (rs1800497) variant are among the most consistently reported genetic contributors to variability in dopamine signalling, receptor availability, and drug metabolism. These variants have been linked to differential therapeutic outcomes, including improved response in some treatment-resistant patients, as well as an increased risk of extrapyramidal symptoms, hyperprolactinaemia, and metabolic disturbances. These findings indicate that genetic variation in the dopaminergic system is a key contributor to differences in antipsychotic response. Integrating pharmacogenomic information in clinical practice may enhance personalised treatment strategies, reduce trial-and-error prescribing, and improve long-term outcomes in schizophrenia. - Source: PubMed
Publication date: 2026/03/27
Olasore Holiness S AOlawale Matthew OAsiwaju Damilare POlashore Anthony A